Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S232000, C546S229000, C546S216000, C514S327000
Reexamination Certificate
active
06964974
ABSTRACT:
The present invention relates to piperidine derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
REFERENCES:
patent: 3133061 (1964-05-01), Kirchner
patent: 3914426 (1975-10-01), Evanega et al.
patent: 5614534 (1997-03-01), Binet et al.
patent: 5681841 (1997-10-01), Himmelsbach et al.
patent: 5994356 (1999-11-01), Himmelsbach et al.
patent: 6034275 (2000-03-01), Aebi et al.
patent: 44 07 961 (1995-09-01), None
patent: 196 18 970 (1997-11-01), None
patent: 198 06 713 (1999-08-01), None
patent: 0 625 509 (1994-11-01), None
patent: 636 367 (1995-02-01), None
patent: WO 94 12181 (1994-06-01), None
patent: WO 95 18619 (1995-07-01), None
Gotto et al., Circulation 81, pp. 1721-1733 (1990).
Stein et al., Nutr. Metab. Cardiovasc. Dis. 2, pp. 113-156 (1992).
Illingworth, Med. Clin. North Am. 84, pp. 23-42 (2000).
Ross et al., Arch. Intern. Med. 159, pp. 1793-1802 (1999).
Ellen et al., J. Cardiol. 81, pp. 60B-65B (1998).
Shepherd, Eur. Heart J. 16, pp. 5-13 (1995).
Davignon et al., Can. J. Cardiol 8, pp. 843-864 (1992).
Pedersen et al., Drug Safety 14, pp. 11-24 (1996).
Morand et al., J. Lipid Research 38, pp. 373-390 (1997).
Mark et al., J. Lipid Research 37, pp. 148-158 (1996).
Peffley et al., Biochem. Pharmacol 56, pp. 439-449 (1998).
Nelson et al., J. Biol. Chem. 256, pp. 1067-1068 (1981).
Spencer et al., J. Biol. Chem. 260, pp. 13391-13394 (1985).
Panini et al., J. Lipid Research 27, pp. 1190-1204 (1986).
Ness et al., Arch. Biochem. Biophys. 308, pp. 420-425 (1994).
Janowski et al., Proc. Natl. Acad. Sci. USA 96, pp. 266-271 (1999).
Venkateswaran et al., J. Biol. Chem. 275, pp. 14700-14707 (2000).
Costet et al., J. Biol. Chem. 275, pp. 28240-28245 (2000).
Ordovas et al., Nutr. Rev. 58, pges. 76-79 (2000).
Schmitz et al., Front. Biosci 6, D505-D514 (2001).
Tobin et al., Mol. Endocrinol. 14, pp. 741-752 (2000).
Marshall et al., J. Org. Chem. 61(17), pp. 5729-5735 (1996).
Baker et al., J. Chem. Soc. Perkin Trans. 1, pp. 1415-1421 (1990).
Belostotkii et al., Tetrahedron Letters 35(28), pp. 5075-5076 (1994).
Bartlett et al., J. Am. Chem. Soc. 106, pp. 7854-7860 (1984).
Cooper et al., Synthesis 4, pp. 621-625 (2001).
Ackermann Jean
Aebi Johannes
Chucholowski Alexander
Dehmlow Henrietta
Morand Olivier
Aulakh Charanjit S.
Hoffmann-La Roche Inc.
Johnston George W.
Tu Peter
LandOfFree
2,3-oxidosqualene-lanosterol cyclase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3-oxidosqualene-lanosterol cyclase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3-oxidosqualene-lanosterol cyclase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454650